Manji, A.; Samson, Y.; Deyell, R.J.; Johnston, D.L.; Lewis, V.A.; Zorzi, A.P.; Berman, J.N.; Brodeur-Robb, K.; Morrison, E.; Kee, L.;
et al. Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. Cancers 2022, 14, 2985.
https://doi.org/10.3390/cancers14122985
AMA Style
Manji A, Samson Y, Deyell RJ, Johnston DL, Lewis VA, Zorzi AP, Berman JN, Brodeur-Robb K, Morrison E, Kee L,
et al. Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. Cancers. 2022; 14(12):2985.
https://doi.org/10.3390/cancers14122985
Chicago/Turabian Style
Manji, Arif, Yvan Samson, Rebecca J. Deyell, Donna L. Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, Kathy Brodeur-Robb, Ellen Morrison, Lynn Kee,
and et al. 2022. "Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial" Cancers 14, no. 12: 2985.
https://doi.org/10.3390/cancers14122985
APA Style
Manji, A., Samson, Y., Deyell, R. J., Johnston, D. L., Lewis, V. A., Zorzi, A. P., Berman, J. N., Brodeur-Robb, K., Morrison, E., Kee, L., Kumar, S., Baruchel, S., Whitlock, J. A., & Morgenstern, D. A.
(2022). Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. Cancers, 14(12), 2985.
https://doi.org/10.3390/cancers14122985
